Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pacira Pharmaceuticals has announced collaboration with Amylin Pharmaceuticals, for the development of sustained release injectable products based on the DepoFoam technology platform from Pacira.
Subscribe to our email newsletter
The companies will work together to enhance the dosing profile for compounds within Amylin’s early R&D pipeline. The goal of the collaboration is to develop multiple products based on sustained release, subcutaneous injection.
Christopher Rhodes, executive director, pharmaceutical sciences of Amylin, said: “This collaboration fits well with Amylin’s R&D activities, which leverage our expertise in metabolism to develop potential therapies for diabetes and obesity.”